Search

Displaying results 5121 - 5130 of 5496 in total
  1. Drug

    Influenza A virus A/Switzerland/9715293/2013 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB11035
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  2. Drug

    Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen

    go.drugbank.com/drugs/DB11037
    ApprovedInvestigationalWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  3. Drug

    Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11040
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  4. Drug

    Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11041
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  5. Drug

    Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11042
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  6. Drug

    Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11046
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  7. Drug

    Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14385
    ApprovedInvestigationalWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  8. Drug

    Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14390
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  9. Drug

    Influenza B virus B/Massachusetts/2/2012 hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14393
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  10. Drug

    Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB14394
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it